Susan Wiviott

Kadmon Holdings, Inc. is a biopharmaceutical company, which engages in discovering, developing, and commercializing small molecules and biologics to address unmet medical need. The company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. The firms late-stage product candidate KD025, which is an orally administered selective inhibitor of Rho-associated coiled-coil kinase engages in development for the treatment of inflammatory and fibrotic diseases. The firm's a pivotal clinical trial of KD025 is underway in chronic graft-versus-host disease (cGVHD), as well as a Phase 2 clinical trial in systemic sclerosis. It is also developing next-generation immuno-oncology therapies, specifically IL-15 containing fusion proteins, for the treatment of cancer. The company's lead I-O product candidate, KD033, is an anti-PD-L1/IL-15 fusion protein. Kadmon was founded by Steven N. Gordon in September 2010 and is headquartered in New York, NY.

The District of Columbia Bar provides legal services. The private company is based in Washington.

Jewish Board of Family & Children's Services, Inc. is a non-profit company that provides website hosting services. The company is based in New York, NY. The company has over 25 years of experience and offer a variety of web hosting plans with 99.9% server uptime. The company's services are supported by 24/7 technical support from real employees.

Palladia, Inc. used to provide healthcare services. The company offered homeless, substance, alcohol addiction Treatment, domestic violence and behavioral heath services. Palladia was founded in 1970 and was headquartered in New York, NY.

Kadmon Corp. LLC manufactures and distributes pharmaceutical products. It currently offers products and services for the treatment and management of hepatitis C, is pioneering medicines in oncology, infectious diseases, and immunology and neurodegenerative diseases by using new understandings in molecular biology to develop therapies that target the metabolomic and signaling pathways associated with disease. The company was founded in 2009 and is headquartered in New York, NY.